PRGOPerrigo Company plc
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−2% a year). Little growth is priced in even as revenue fell 4% a year over three years, potential value, or a value trap.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PRGO's price assumes
Today's price asks for −2.1% free cash flow growth a year; over the last three years Perrigo Company plc delivered −19%, the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 8.9%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- −2.1%
Growth the price implies · The price pays for −2.1% free cash flow growth a year for a decade; the business has delivered −19% a year over the last three.
- Price / book
- 0.54
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 0.54
- EV / EBIToperating margin −38%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 1.02
- Free cash flow, trailing twelve months
- $119M
- Market capitalisation
- $1.34B
- 3-year revenue growth
- −3.6%
- 3-year free cash flow growth
- −19%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #23 of 41 by RyuScore